Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC
出版年份 2021 全文链接
标题
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC
作者
关键词
ALK/HDAC dual Inhibitors, Pharmacophore merged strategy, 2,4-Pyrimidinediamine, NSCLC
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 224, Issue -, Pages 113672
出版商
Elsevier BV
发表日期
2021-06-29
DOI
10.1016/j.ejmech.2021.113672
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of New Inhibitors of Transforming Growth Factor-Beta Type 1 Receptor by Utilizing Docking and Structure-Activity Relationship Analysis
- (2019) Jiang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants
- (2019) Wenteng Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Enhancer remodeling and microRNA alterations are associated with acquired resistance to ALK inhibitors
- (2018) Mi Ran Yun et al. CANCER RESEARCH
- A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment
- (2018) Jing Shen et al. CELL DEATH AND DIFFERENTIATION
- Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R
- (2018) Yu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation
- (2018) Kaijun Geng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
- (2018) Yongtao Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R
- (2017) Gangadhar Rao Mathi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First macrocyclic 3 rd -generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib
- (2017) Sulman Basit et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat
- (2017) Lianbin Yao et al. JOURNAL OF MEDICINAL CHEMISTRY
- MA07.10 HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells
- (2017) Koji Fukuda et al. Journal of Thoracic Oncology
- Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Crizotinib resistance: implications for therapeutic strategies
- (2016) I. Dagogo-Jack et al. ANNALS OF ONCOLOGY
- Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1
- (2016) Yu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
- (2016) Xuyuan Dong et al. NEOPLASIA
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
- (2014) Tatsushi Kodama et al. CANCER LETTERS
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
- (2014) C. M. Lovly et al. Cancer Discovery
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started